This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Stathmin-2 (STMN2) is a microtubule-associated protein that has a major role in axonal development and repair. STMN2 promotes microtubule instability necessary for normal axonal outgrowth and regeneration. The expression of STMN2 is strongly regulated by nuclear transactive response DNA-binding protein 43 kDA (TDP-43). This multifunctional nucleic acid binding protein is a primary component of insoluble cytoplasmic aggregates associated with several neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) resulting in frontotemporal dementia (FTD). Recent evidence indicates that reduced nuclear TDP-43 function leads to improper splicing of the gene encoding STMN2, leading to the production of a truncated protein.1,2 This finding provides a mechanistic link between TDP-43 proteinopathies and axonal degeneration.1,3
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
See the Highlighted Changes supplement, showing the changes made in this updated version: http://links.lww.com/WNL/B642.
- Received June 4, 2021.
- Accepted in final form June 4, 2021.
- © 2021 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
